Epithelioid
Perioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
Interdisciplinary Cardiovascular Thoracic Surgery 2023 November 2 [Link] Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff, David Waller Abstract Objectives: The goal was to evaluate the accuracy of preoperative histological assessment and the factors affecting the accuracy and the subsequent effect on postoperative survival after surgical treatment for malignant pleural mesothelioma (MPM). Methods:…
Read MoreGelatinous Pleural Effusion: A Diagnostic Challenge for Pleural Mesothelioma in an 80-Year-Old Man
American Journal of Case Reports 2023 October 4 [Link] Ali M Ibnian, Obaid Ullah Khan, Richard Chan, Umesh Bangalore Lakshminarayana, Fasiha Kiran, Sarah Abed, Rahim Abbas, Ahsan Amir, Noran K Al-Kofahi Abstract BACKGROUND Gelatinous pleural effusion, due to raised hyaluronic acid, can be associated with pleural infection and malignancies, such as tuberculosis, metastatic pleural disease,…
Read MoreUroplakin-IIIb as a novel immunohistochemical marker for mesothelioma
Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…
Read MoreUroplakin-IIIb as a novel immunohistochemical marker for mesothelioma
Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…
Read MoreUroplakin-IIIb as a novel immunohistochemical marker for mesothelioma
Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…
Read MoreNew Immunohistochemical Markers for Pleural Mesothelioma Subtyping
Diagnostics 2023 September 14 [Link] Iosè Di Stefano, Greta Alì, Anello Marcello Poma, Rossella Bruno, Agnese Proietti, Cristina Niccoli, Carmelina Cristina Zirafa, Franca Melfi, Maria Giovanna Mastromarino, Marco Lucchi, Gabriella Fontanini Abstract Pleural mesothelioma (PM) comprises three main subtypes: epithelioid, biphasic and sarcomatoid, which have different impacts on prognosis and treatment definition. However, PM subtyping…
Read MoreEpithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair
Cancers 2023 August 29 [Link] Monica Ganzinelli, Federica Guffanti, Anna Ianza, Navid Sobhani, Sergio Crovella, Fabrizio Zanconati, Cristina Bottin, Marco Confalonieri, Stefano Fumagalli, Alessandra Guglielmi, Daniele Generali, Giovanna Damia Abstract Aim: DNA repair has an important role in malignant pleural mesothelioma (MPM) tumorigenesis and progression. Prognostic/predictive biomarkers for better management of MPM patients are needed.…
Read MoreMalignant Mesothelioma subtyping via sampling driven multiple instance prediction on tissue image and cell morphology data
Artificial Intelligence in Medicine 2023 September [Link] Mark Eastwood, Silviu Tudor Marc, Xiaohong Gao, Heba Sailem, Judith Offman, Emmanouil Karteris, Angeles Montero Fernandez, Danny Jonigk, William Cookson, Miriam Moffatt, Sanjay Popat, Fayyaz Minhas, Jan Lukas Robertus Abstract Malignant Mesothelioma is a difficult to diagnose and highly lethal cancer usually associated with asbestos exposure. It can…
Read MoreExtrathoracic Metastases in Pleural Mesothelioma
JTO Clinical and Research Reports 2023 August 2 [Link] Ibiayi Dagogo-Jack, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy Abstract Introduction: Guidelines recommend obtaining a computed tomography scan of the chest for the staging of pleural mesothelioma and for assessing response to treatment. Consensus is lacking regarding the necessity of serial imaging of distant extrathoracic…
Read MoreZimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature
World Journal of Clinical Cases 2023 August 6 [Link] Xiao-Dong Peng, Zhen-Yu You, Lian-Xiang He, Qi Deng Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare cancer with a poor prognosis at advanced stage, and the standard first-line treatment for inoperable patients is chemotherapy. Although combining programmed cell death 1 (PD-1) inhibitors with chemotherapy is…
Read More